Accessibility Menu
 
Actinium Pharmaceuticals logo

Actinium Pharmaceuticals

(NYSEMKT) ATNM

Current Price$0.99
Market Cap$30.76M
Since IPO (2013)-99%
5 Year-88%
1 Year-36%
1 Month-12%

Actinium Pharmaceuticals Financials at a Glance

Market Cap

$30.76M

Revenue (TTM)

$90.00K

Net Income (TTM)

$33.89M

EPS (TTM)

$-1.09

P/E Ratio

-0.90

Dividend

$0.00

Beta (Volatility)

1.42 (Average)

Price

$0.99

Volume

59,349.529

Open

$0.99

Previous Close

$0.98

Daily Range

$0.98 - $1.01

52-Week Range

$0.95 - $1.95

ATNM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Actinium Pharmaceuticals

Industry

Biotechnology

Employees

25

CEO

Sandesh Seth, MBA

Headquarters

New York City, NY 10016, US

ATNM Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-403%

Net Income Margin

-377%

Return on Equity

-167%

Return on Capital

-83%

Return on Assets

-65%

Earnings Yield

-1.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$30.76M

Shares Outstanding

31.38M

Volume

59.35K

Short Interest

0.00%

Avg. Volume

120.51K

Financials (TTM)

Gross Profit

$90.00K

Operating Income

$36.25M

EBITDA

$35.43M

Operating Cash Flow

$24.58M

Capital Expenditure

$104.00K

Free Cash Flow

$24.68M

Cash & ST Invst.

$48.00M

Total Debt

$1.69M

Actinium Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$615.00K

+401.5%

Gross Margin

0.00%

N/A

Market Cap

$30.76M

N/A

Market Cap/Employee

$992.26K

N/A

Employees

31

N/A

Net Income

$5.94M

+10.7%

EBITDA

$8.91M

-38.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$46.30M

-35.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$972.00K

-2.1%

Short Term Debt

$722.00K

+24.5%

Return on Assets

-65.45%

N/A

Return on Invested Capital

-82.74%

N/A

Free Cash Flow

$5.39M

+6.2%

Operating Cash Flow

$5.29M

+8.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TVRDTvardi Therapeutics, Inc.
$3.02+0.67%
PDSBPDS Biotechnology Corporation
$0.64+4.73%
FGENFibroGen, Inc.
$9.07-1.63%
ANVSAnnovis Bio, Inc.
$2.28+7.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%
NOKNokia
$8.82+0.07%

Questions About ATNM

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.